FibroGen Inc (FGEN)
2.35
-0.23
(-8.91%)
USD |
NASDAQ |
Mar 28, 16:00
2.36
+0.01
(+0.43%)
After-Hours: 20:00
FibroGen Cash from Financing (TTM): 122.75M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 122.75M |
September 30, 2023 | 171.67M |
June 30, 2023 | 170.60M |
March 31, 2023 | 81.15M |
December 31, 2022 | 46.78M |
September 30, 2022 | -1.929M |
June 30, 2022 | -1.67M |
March 31, 2022 | -1.376M |
December 31, 2021 | -0.563M |
September 30, 2021 | 5.127M |
June 30, 2021 | 10.18M |
March 31, 2021 | 12.45M |
December 31, 2020 | 13.34M |
September 30, 2020 | 7.40M |
June 30, 2020 | -0.061M |
March 31, 2020 | -1.956M |
December 31, 2019 | -4.30M |
September 30, 2019 | -1.198M |
June 30, 2019 | 5.958M |
Date | Value |
---|---|
March 31, 2019 | 8.296M |
December 31, 2018 | 13.88M |
September 30, 2018 | 14.47M |
June 30, 2018 | 380.58M |
March 31, 2018 | 497.94M |
December 31, 2017 | 496.47M |
September 30, 2017 | 496.20M |
June 30, 2017 | 127.27M |
March 31, 2017 | 7.461M |
December 31, 2016 | 6.738M |
September 30, 2016 | 7.718M |
June 30, 2016 | 9.443M |
March 31, 2016 | 11.58M |
December 31, 2015 | 12.35M |
September 30, 2015 | 183.88M |
June 30, 2015 | 180.04M |
March 31, 2015 | 174.78M |
December 31, 2014 | 174.09M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-4.30M
Minimum
Dec 2019
171.67M
Maximum
Sep 2023
32.13M
Average
6.679M
Median
Cash from Financing (TTM) Benchmarks
Emergent BioSolutions Inc | -535.70M |
Geron Corp | 362.02M |
Regulus Therapeutics Inc | 11.82M |
Fate Therapeutics Inc | 0.085M |
Genprex Inc | 10.60M |